A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Brivanib alaninate (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms BRISK-FL
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 26 Aug 2013 Results published in the Journal of Clinical Oncology.
    • 25 Mar 2013 Status changed from active, no longer recruiting to completed as reported by Last checked against Clinical Trials Registry - India.
    • 02 Nov 2012 Results will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top